Tumor necrosis factor in lung cancer: Complex roles in biology and resistance to treatment

Tumor necrosis factor in lung cancer: Complex roles in biology and resistance to treatment

Tumor necrosis factor (TNF) and its receptors are widely expressed in non-small cell lung cancer (NSCLC). TNF has an established role in inflammation and also plays a key role in inflammation-induced cancer. TNF can induce cell death in cancer cells and has been used as a treatment in certain types...

Full description

Bibliographic Details
Main Authors:	Ke Gong, Gao Guo, Nicole Beckley, Yue Zhang, Xiaoyao Yang, Mishu Sharma, Amyn A. Habib
Format:	Article
Language:	English
Published:	Elsevier 2021-02-01
Series:	Neoplasia: An International Journal for Oncology Research
Subjects:	TNF NSCLC EGFR inhibition Therapeutic resistance Immunotherapy TCGA
Online Access:	http://www.sciencedirect.com/science/article/pii/S1476558620301871

Similar Items

Rescue Surgery after Immunotherapy/Tyrosine Kinase Inhibitors for Initially Unresectable Lung Cancer
by: Domenico Galetta, et al.
Published: (2022-05-01)

Immune-checkpoint Inhibitor Treatment of Non-Small Cell Lung Cancer Patients
by: Haryati, et al.
Published: (2020-01-01)

Therapy for patients with non-small cell lung cancer in the Russian Federation: EPICLIN-Lung study
by: S A Tyulyandin, et al.
Published: (2016-12-01)

Comprehensive profiling of EGFR mutation subtypes reveals genomic-clinical associations in non-small-cell lung cancer patients on first-generation EGFR inhibitors
by: Yongkang Bai, et al.
Published: (2023-04-01)

Case Report: Long Progression-Free Survival of Immunotherapy for Lung Adenocarcinoma With Epidermal Growth Factor Receptor Mutation
by: Jianfeng Peng, et al.
Published: (2021-09-01)

Uncommon and Rare <i>EGFR</i> Mutations in Non-Small Cell Lung Cancer Patients with a Focus on Exon 20 Insertions and the Phase 3 PAPILLON Trial: The State of the Art
by: Federico Pio Fabrizio, et al.
Published: (2024-03-01)

Takotsubo cardiomyopathy Afatinib-related in a non-small cell lung cancer patient: Case report
by: German E. Ramos, et al.
Published: (2022-11-01)

LINC01572 is a Novel Prognostic Biomarker and Therapeutic Target in Lung Adenocarcinoma
by: Yaolin Zheng, et al.
Published: (2023-10-01)

Advances in Targeted Therapy and Immunotherapy for Non-small Cell Lung Cancer Based on Accurate Molecular Typing
by: Jingsi Dong, et al.
Published: (2019-03-01)

EGFR Mutations Are Not All the Same: the Importance of Biomarker Testing in Non-small Cell Lung Cancer (NSCLC)—A Podcast Discussion Between Patients and Oncologists
by: Stephen V. Liu, et al.
Published: (2023-09-01)

An autophagy-associated lncRNAs model for predicting the survival in non-small cell lung cancer patients
by: Jing Hu, et al.
Published: (2022-09-01)

Comprehensive Molecular Analyses of a TNF Family-Based Gene Signature as a Potentially Novel Prognostic Biomarker for Cervical Cancer
by: Yan Ma, et al.
Published: (2022-03-01)

Evaluation of current methods to detect the mutations of epidermal growth factor receptor in non-small cell lung cancer patients
by: Obradovic Jasmina, et al.
Published: (2012-12-01)

The prognostic impact of neutrophil to lymphocyte ratio in advanced non-small-cell lung cancer patients treated with EGFR TKI
by: Phan TT, et al.
Published: (2018-11-01)

Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance
by: Kai Fu, et al.
Published: (2022-12-01)

The Biological and Clinical Relevance of Inhibitor of Growth (ING) Genes in Non-Small Cell Lung Cancer
by: Elisabeth Smolle, et al.
Published: (2019-08-01)

Overcoming T790M mutant small cell lung cancer with the third‐generation EGFR‐TKI osimertinib
by: Kejing Tang, et al.
Published: (2019-02-01)

Longitudinal Circulating Tumor DNA Analysis in Blood and Saliva for Prediction of Response to Osimertinib and Disease Progression in EGFR-Mutant Lung Adenocarcinoma
by: Chul Kim, et al.
Published: (2021-07-01)

Is ICI-based therapy better than chemotherapy for metastatic NSCLC patients who develop EGFR-TKI resistance? A real-world investigation
by: Yajie Cheng, et al.
Published: (2022-08-01)

Ligand-based, piggyBac-engineered CAR-T cells targeting EGFR are safe and effective against non-small cell lung cancers
by: Thanyavi Chinsuwan, et al.
Published: (2023-12-01)

Central nervous system progression in advanced non–small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study
by: Meng-Xia Li, et al.
Published: (2017-04-01)

OPALS: A New Osimertinib Adjunctive Treatment of Lung Adenocarcinoma or Glioblastoma Using Five Repurposed Drugs
by: Richard E. Kast, et al.
Published: (2021-05-01)

FBXW7 deletion contributes to lung tumor development and confers resistance to gefitinib therapy
by: Yi Xiao, et al.
Published: (2018-06-01)

Identifying Robust Radiomics Features for Lung Cancer by Using In-Vivo and Phantom Lung Lesions
by: Lin Lu, et al.
Published: (2021-02-01)

Mechanisms of EGFR-TKI-Induced Apoptosis and Strategies Targeting Apoptosis in EGFR-Mutated Non-Small Cell Lung Cancer
by: Shigetoshi Nishihara, et al.
Published: (2022-11-01)

Differential Expression of RBM5, EGFR and KRAS mRNA and protein in non-small cell lung cancer tissues
by: Liang Hong, et al.
Published: (2012-04-01)

Epidermal growth factor receptor-mutated non-small-cell lung cancer: A primer on contemporary management
by: Akhil Rajendra, et al.
Published: (2019-01-01)

Human skin biomarkers relationship to response to treatment with tyrosine kinase inhibitors in advanced EGFR‐mutated lung adenocarcinoma
by: Anahí Castañeda‐Zárraga, et al.
Published: (2020-11-01)

EGFR‐plasma mutations in prognosis for non‐small cell lung cancer treated with EGFR TKIs: A meta‐analysis
by: Thang Thanh Phan, et al.
Published: (2022-08-01)

Impact of obesity on the response to tumor necrosis factor inhibitors in axial spondyloarthritis
by: Raphael Micheroli, et al.
Published: (2017-07-01)

A brief report on the mutational landscape in non-small cell lung cancer of South Asian patients: Comparison at a US and an Indian Institution
by: Mohana Roy, et al.
Published: (2022-01-01)

Design, synthesis and biological evaluation of novel 4-anlinoquinazoline derivatives as EGFR inhibitors with the potential to inhibit the gefitinib-resistant nonsmall cell lung cancers
by: Caolin Wang, et al.
Published: (2019-01-01)

Case Report: Aumolertinib as Neoadjuvant Therapy for Patients With Unresectable Stage III Non-Small Cell Lung Cancer With Activated EGFR Mutation: Case Series
by: Shao Feng, et al.
Published: (2022-03-01)

The relationship between PD-L1 expression and tumor driver gene mutations and survival in non small cell lung carcinoma
by: Kin Chan, et al.
Published: (2022-01-01)

Efficacy and Safety of Combination Treatment With Apatinib and Osimertinib After Osimertinib Resistance in Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Carcinoma—A Retrospective Analysis of a Multicenter Clinical Study
by: Xue Yang, et al.
Published: (2021-05-01)

Prognostic Value of Albumin-to-Alkaline Phosphatase Ratio for EGFR-Mutated Advanced Non-Small-Cell Lung Cancer Patients Treated with First-Line EGFR-TKIs: A Large Population-Based Study and Literature Review
by: Gan Y, et al.
Published: (2022-03-01)

Compound 15c, a Novel Dual Inhibitor of EGFRL858R/T790M and FGFR1, Efficiently Overcomes Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Resistance of Non-Small-Cell Lung Cancers
by: Gaozhi Chen, et al.
Published: (2020-01-01)

Development of 10-Hydroxycamptothecin-crizotinib conjugate based on the synergistic effect on lung cancer cells
by: Zhen Liu, et al.
Published: (2023-12-01)

Making NSCLC Crystal Clear: How Kinase Structures Revolutionized Lung Cancer Treatment
by: Juliana F. Vilachã, et al.
Published: (2020-08-01)

Molecular and Clinical Features of EGFR-TKI-Associated Lung Injury
by: Tohru Ohmori, et al.
Published: (2021-01-01)